This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:mp:olmesartan:response [08.23.2017] – [Increase in immunopathology] sallieq | home:mp:olmesartan:response [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Patient response to olmesartan (Benicar) | ====== Patient response to olmesartan (Benicar) | ||
+ | |||
+ | < | ||
+ | |||
Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, | Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, | ||
Line 30: | Line 33: | ||
< | < | ||
- | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[http:// | + | Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[https:// |
For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home: | ||
- | {{tag> | + | {{tag>MP olmesartan}} |
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
* Legacy content | * Legacy content | ||
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
- | * http:// | + | * https:// |
===== References ===== | ===== References ===== | ||
- | + | </ |